The Australasian journal of dermatology · 2025
Health Equity and Secukinumab for Severe Psoriasis in New Zealand.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Anna, Oakley Amanda, Han Dug Yeo, Jarrett Paul
Аннотация
BACKGROUND/OBJECTIVES: The only funded indication in New Zealand between October 2018 and April 2021 for the biologic secukinumab, an interleukin-17A antibody, was severe psoriasis. This unique period of limited availability of secukinumab allowed the evaluation of who received it and health equity.
METHODS: Anonymised dispensing data were obtained from the New Zealand Ministry of Health and matched with the New Zealand deprivation index, ethnicity and census data.
RESULTS: Compared to the most socio-economically deprived, the least deprived were significantly more likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 4.00 (3.29-4.71) and 6.56 (5.61-7.51) p < 0.0001. Compared to European ethnicity, Māori, Pacific peoples and Asian were less likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 6.30 (5.81-6.79), 3.27 (2.56-3.99), 3.31 (2.28-4.33), 4.33 (3.48-5.19) p < 0.0001 all groups.
CONCLUSIONS: Between October 2018 and April 2021, the data suggest that the dispensing of secukinumab was inequitable. Those having severe psoriasis and being socio-economically disadvantaged or of Māori, Pacific and Asian compared to European ethnicity, were significantly less likely to have received secukinumab. Dermatologist workforce shortages in New Zealand are likely to compound the problem.
METHODS: Anonymised dispensing data were obtained from the New Zealand Ministry of Health and matched with the New Zealand deprivation index, ethnicity and census data.
RESULTS: Compared to the most socio-economically deprived, the least deprived were significantly more likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 4.00 (3.29-4.71) and 6.56 (5.61-7.51) p < 0.0001. Compared to European ethnicity, Māori, Pacific peoples and Asian were less likely to receive secukinumab, respectively, dispensing rates per 100,000 (95% confidence interval) 6.30 (5.81-6.79), 3.27 (2.56-3.99), 3.31 (2.28-4.33), 4.33 (3.48-5.19) p < 0.0001 all groups.
CONCLUSIONS: Between October 2018 and April 2021, the data suggest that the dispensing of secukinumab was inequitable. Those having severe psoriasis and being socio-economically disadvantaged or of Māori, Pacific and Asian compared to European ethnicity, were significantly less likely to have received secukinumab. Dermatologist workforce shortages in New Zealand are likely to compound the problem.